-
-
Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce mortality and myocardial infarction (MI) in patients with heart failure due to reduced left ventricular (LV) systolic function.
-
Discontinuation of anticoagulation 3-6 months after successful atrial fibrillation ablation is reasonable in low-risk patients.
-
Among elderly persons without chronic kidney disease, cystatin C is a prognostic biomarker of risk for death, cardiovascular disease, and chronic kidney disease.
-
-
-
A team from UCSF recently reviewed company documents that were entered into the public record as a result of litigation over the promotion of gabapentin (Neurontin) between 1994 and 1998.
-
In ACS patients without persistent ST-segment elevation, there is a strong, consistent, temporal, and dose-related association between bleeding and death.
-
The 2006 guidelines for the management of patients with atrial fibrillation clarify previous recommendations for anticoagulation to prevent other thromboembolic events.
-
ACE inhibitors are associated with a reduced risk of ruptured abdominal aortic aneurysm, unlike other antihypertensive agents. Randomised trials of ACE inhibitors for prevention of aortic rupture might be warranted.
